Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

242.14
+1.310.54%
Volume:132.27K
Turnover:32.14M
Market Cap:15.72B
PE:16.55
High:244.36
Open:242.93
Low:241.76
Close:240.83
52wk High:266.38
52wk Low:124.47
Shares:64.91M
Float Shares:62.69M
Volume Ratio:0.70
T/O Rate:0.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.27
PE(LYR):-41.46

Loading ...

Jazz Pharmaceuticals - Deal Expected to Close by Q4 2026, Subject to Conditions

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals - to Fund Deal with Cash on Hand and Existing Financing Facilities

THOMSON REUTERS
·
Aug 10

Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 06

UBS Adjusts Jazz Pharmaceuticals Price Target to $315 From $307, Maintains Buy Rating

MT Newswires Live
·
Aug 05

Jazz Pharmaceuticals price target raised to $300 from $290 at Canaccord

TIPRANKS
·
Aug 05

Jazz Pharmaceuticals (JAZZ) Stock Climbs As Raised Guidance Backs Oncology Push

Simply Wall St.
·
Aug 05

Jazz Pharmaceuticals Delivers Strong Q2, Xywav Drives Higher Guidance, Morgan Stanley Says

MT Newswires Live
·
Aug 04

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Benzinga Earnings
·
Aug 04

Jazz Pharmaceuticals is Maintained at Outperform by Baird

Dow Jones
·
Aug 04

Jazz Pharmaceuticals price target raised to $270 from $260 at Barclays

TIPRANKS
·
Aug 04

Morgan Stanley Adjusts PT on Jazz Pharmaceuticals to $280 From $245, Maintains Overweight Rating

MT Newswires Live
·
Aug 04

Pharma Mar Says Jazz Pharmaceuticals to Seek FDA Withdrawal of Zepzelca Second-Line Use

Reuters
·
Aug 04

Jazz Pharmaceuticals Plc : Baird Raises Target Price to $280 from $252

THOMSON REUTERS
·
Aug 04

Analysts Offer Insights on Healthcare Companies: HealthStream (HSTM) and Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 04

Jazz Pharmaceuticals PLC Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

GUIDANCE: (JAZZ) Jazz Pharmaceuticals Expects Full Year 2026 Revenue Range $4.60B - $4.75B, vs. FactSet Est of $4.51B

MT Newswires Live
·
Aug 04

Jazz Q2 FY26 GAAP EPS Rises 16% to $2.78; Revenue Increases 16% to $1.21 Billion

Reuters
·
Aug 04

Jazz Pharmaceuticals Q2 Adjusted EPS USD 5.71 Vs. IBES Estimate USD 6.18

Reuters
·
Aug 04

Jazz Pharmaceuticals Q2 EPS USD 2.78

THOMSON REUTERS
·
Aug 04